MyBiotics has developed a range of innovative technologies aimed at enhancing the efficacy of biotherapeutic products derived from human microbiota. Central to their approach is the MyCrobe™ technology, which focuses on single-strain fermentation and formulation processes that ensure the survival and effective colonization of beneficial bacteria in the human gut. This technology allows for the production of highly stable probiotic products that can withstand harsh gastrointestinal conditions, thereby improving their clinical potential. Additionally, MyBiotics employs the SuperDonor™ technology, which enables the replication of specific human microbiome samples, facilitating the development of treatments that can restore microbiome balance in patients. This technology is particularly significant as it aims to replace traditional fecal microbiota transplants (FMT) with a more standardized and scalable solution.

Furthermore, MyBiotics integrates advanced computational tools through its MyLiveIn program, which utilizes artificial intelligence to design unique microbial consortia tailored to individual patient needs. This platform enhances the understanding of bacterial interactions and supports the development of personalized microbiome therapies. The company is also focused on addressing various health issues, including gastrointestinal disorders, women's health, and oncology, with products like MBX-SD-201 and MBX-SD-202 targeting Clostridium difficile infections. Overall, MyBiotics is at the forefront of microbiome research, leveraging its proprietary technologies to create effective therapeutic solutions that aim to restore and maintain microbiome equilibrium in patients.

Israel

MyBiotics is an innovative life science company active in the Microbiome field. 
The company develops Pharmabiotics products and drugs based on indication specific bacterial mix combined with its proprietary and highly efficient delivery technologies. MyBiotics developed a unique highly efficient live and colonizing bacteria delivery technologies
MyCrobe and SuperDonor technologies allow highly efficient and clinically proven bacterial targeted release, these technology will be used for Microbiome restoration and a long list of medical indications. 
The company completed pre-clinical experiments and will start its clinical trials in 2016.

MyBiotics

Company Details